Italian clinical research in non-small-cell lung cancer

Cesare Gridelli, A. Rossi, D. Galetta, P. Maione, C. Ferrara, C. Guerriero, F. Del Gaizo, D. Nicolella, G. Colantuoni, V. Gebbia, G. Colucci

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15-20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC patients. In particular, Italy is leader in the clinical research of the treatment of advanced NSCLC elderly patients. Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC.

Original languageEnglish
JournalAnnals of Oncology
Volume16
Issue numberSUPPL. 4
DOIs
Publication statusPublished - May 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Research
Italy
Lung Neoplasms
Controlled Clinical Trials
Cause of Death
Neoplasms
Therapeutics
Survival

Keywords

  • Italian clinical research
  • Lung cancer
  • NSCLC

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gridelli, C., Rossi, A., Galetta, D., Maione, P., Ferrara, C., Guerriero, C., ... Colucci, G. (2005). Italian clinical research in non-small-cell lung cancer. Annals of Oncology, 16(SUPPL. 4). https://doi.org/10.1093/annonc/mdi919

Italian clinical research in non-small-cell lung cancer. / Gridelli, Cesare; Rossi, A.; Galetta, D.; Maione, P.; Ferrara, C.; Guerriero, C.; Del Gaizo, F.; Nicolella, D.; Colantuoni, G.; Gebbia, V.; Colucci, G.

In: Annals of Oncology, Vol. 16, No. SUPPL. 4, 05.2005.

Research output: Contribution to journalArticle

Gridelli, C, Rossi, A, Galetta, D, Maione, P, Ferrara, C, Guerriero, C, Del Gaizo, F, Nicolella, D, Colantuoni, G, Gebbia, V & Colucci, G 2005, 'Italian clinical research in non-small-cell lung cancer', Annals of Oncology, vol. 16, no. SUPPL. 4. https://doi.org/10.1093/annonc/mdi919
Gridelli C, Rossi A, Galetta D, Maione P, Ferrara C, Guerriero C et al. Italian clinical research in non-small-cell lung cancer. Annals of Oncology. 2005 May;16(SUPPL. 4). https://doi.org/10.1093/annonc/mdi919
Gridelli, Cesare ; Rossi, A. ; Galetta, D. ; Maione, P. ; Ferrara, C. ; Guerriero, C. ; Del Gaizo, F. ; Nicolella, D. ; Colantuoni, G. ; Gebbia, V. ; Colucci, G. / Italian clinical research in non-small-cell lung cancer. In: Annals of Oncology. 2005 ; Vol. 16, No. SUPPL. 4.
@article{3341b70acd8646bcbc5b985c6ca96cd8,
title = "Italian clinical research in non-small-cell lung cancer",
abstract = "Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80{\%} of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15-20{\%} of tumours can be radically resected with a survival of about 40{\%} at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC patients. In particular, Italy is leader in the clinical research of the treatment of advanced NSCLC elderly patients. Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC.",
keywords = "Italian clinical research, Lung cancer, NSCLC",
author = "Cesare Gridelli and A. Rossi and D. Galetta and P. Maione and C. Ferrara and C. Guerriero and {Del Gaizo}, F. and D. Nicolella and G. Colantuoni and V. Gebbia and G. Colucci",
year = "2005",
month = "5",
doi = "10.1093/annonc/mdi919",
language = "English",
volume = "16",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Italian clinical research in non-small-cell lung cancer

AU - Gridelli, Cesare

AU - Rossi, A.

AU - Galetta, D.

AU - Maione, P.

AU - Ferrara, C.

AU - Guerriero, C.

AU - Del Gaizo, F.

AU - Nicolella, D.

AU - Colantuoni, G.

AU - Gebbia, V.

AU - Colucci, G.

PY - 2005/5

Y1 - 2005/5

N2 - Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15-20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC patients. In particular, Italy is leader in the clinical research of the treatment of advanced NSCLC elderly patients. Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC.

AB - Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15-20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC patients. In particular, Italy is leader in the clinical research of the treatment of advanced NSCLC elderly patients. Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC.

KW - Italian clinical research

KW - Lung cancer

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=30644460382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644460382&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi919

DO - 10.1093/annonc/mdi919

M3 - Article

VL - 16

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 4

ER -